跳至主要内容
临床试验/ACTRN12613000387729
ACTRN12613000387729已完成2 期

Adult patients with oesophageal-gastric cancer, to undergo an EUS guided fiducial insertion to mark the tumour in this phase II feasibility study for surgical pathological localisation and chemotherapy response assessment.

Austin Health0 个研究点目标入组 20 人开始时间: 2013年4月10日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
Austin Health
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 99 Years(—)
性别
All

入选标准

  • Age>18yrs with biopsy proven primary (non-recurrent) squamous cell carcinoma (SCC)or adenocarcinoma of the stomach discussed at the upper gastro-intestinal multidisciplinary team meeting (MDT) were considered eligible if they fulfilled the inclusion criteria. These criteria included cancer stage (T1-3,N0-1,M0-1a), ECOG 0 or 1, medically suitable for oeosphagectomy and chemotherapy and or chemoradiotherapy, and written informed consent.

排除标准

  • Contraindications to CT contrast e.g. severe chronic kidney disease, allergy to contrast
  • Contraindications to PET/CT e.g. claustrophobia

研究者

发起方
Austin Health

相似试验